openPR Logo
Press release

Global Hypoparathyroidism Drug Market growth of 8.1% CAGR in the forecast 2019-2026 | Key Analysis- GlaxoSmithKline Plc (UK), Takeda Pharmaceutical Company Limited (Japan), Sun Pharmaceutical Industries Ltd. (India), TESARO Inc.(US), Amgen Inc. (US)

06-25-2019 09:57 PM CET | Health & Medicine

Press release from: Data Bridge Market Research

/ PR Agency: Data Bridge Market Research
Global Hypoparathyroidism Drug Market

Global Hypoparathyroidism Drug Market

The Global Hypoparathyroidism Drug Market research report incorporates a significant synopsis of the key parts and the portions both rapidly and gradually developing divisions of the market. Global hypoparathyroidism drug market growth of 8.1% CAGR in the forecast period of 2019-2026, The market size, share of the market, and every segment based on various factors and sub-portion has been inspected through this examination. The key best in class chances related to the most rapidly developing portions of the Global Hypoparathyroidism Drug Market are likewise a crucial part of the report. The report is bifurcated dependent on the item type, application, topography, end-clients, and more according to the specific market. The geological sections are further thoroughly referenced.

Available a Copy of Sample Report Now! @ https://databridgemarketresearch.com/request-a-sample/?dbmr=global-hypoparathyroidism-drug-market

Market Analysis: Global Hypoparathyroidism Drug Market

Global hypoparathyroidism drug market is expected to grow at a substantial growth of 8.1% CAGR in the forecast period of 2019-2026. The emergence of drugs used in thyroid diseases, increases number of thyroid cancer, development of newer technologies and vulnerable hypoparathyroidism patients enhancing the market growth.

Key Market Players:

Few of the major competitors currently working in the hypoparathyroidism drug market are-Teva Pharmaceutical Industries Ltd (Israel), EnteraBio Ltd. (Israel), F. Hoffmann-La Roche Ltd (Switzerland), Pfizer Inc. (US), Merck KGaA (Germany), GlaxoSmithKline Plc (UK), Takeda Pharmaceutical Company Limited (Japan), Sun Pharmaceutical Industries Ltd (India), TESARO, Inc.(US), Amgen, Inc. (US), Ascendis Pharma A/S (Denmark) and among others.

Key Developments in the Market:

In February 2017, Amgen, Inc. received the FDA approval Parsabiv (etelcalcetide) for the treatment of secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) who have been on hemodialysis. Parsabiv is a novel calcimimetic agent which is given intravenously by the dialysis specialist at the end of hemodialysis session.

In June 2018, Ascendis Pharma A/S received the FDA Orphan Drug Designation for TransCon PTH for the treatment of TransCon PTH is a long acting parathyroid hormone replacement therapy which helps in restoring the activity of parathyroid hormone.

More Details | Inquiry Before Buying and Discuss Report Customization with Industry Expert @ https://databridgemarketresearch.com/inquire-before-buying/?dbmr=global-hypoparathyroidism-drug-market

Competitive Analysis:

Global hypoparathyroidism drug market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of hypoparathyroidism drug market for Global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.

Potential of the report :
• Key developments and product launches in the market
• To get a comprehensive overview of the Global Hypoparathyroidism Drug Market.
• Key parameters which are driving the market
• Strategies of key players and product offerings
• In-depth market segmentation

Contact Us-

Data Bridge Market Research
US: +1-888-387-2818
Email: sopan.gedam@databridgemarketresearch.com

About Us:

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with an unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to complex business challenges and initiates an effortless decision-making process.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Global Hypoparathyroidism Drug Market growth of 8.1% CAGR in the forecast 2019-2026 | Key Analysis- GlaxoSmithKline Plc (UK), Takeda Pharmaceutical Company Limited (Japan), Sun Pharmaceutical Industries Ltd. (India), TESARO Inc.(US), Amgen Inc. (US) here

News-ID: 1787879 • Views:

More Releases from Data Bridge Market Research

Unveiling the Power: Radio Frequency Identification (RFID) Middleware in Modern Operations
Unveiling the Power: Radio Frequency Identification (RFID) Middleware in Modern …
Data Bridge Market Research analyses that the radio frequency identification (RFID) middleware market will exhibit a CAGR of 10.15% for the forecast period of 2022-2022 and is expected to reach the market value of USD 5.03 billion by 2029. Radio Frequency Identification (RFID) refers to a wireless system comprised of two components tags and readers. The reader is a device that has one or more antennas that emit radio waves and
Streamlining Service: Innovations in Hospitality Management Software
Streamlining Service: Innovations in Hospitality Management Software
The hospitality management software market is expected to witness market growth at a rate of 8.37% in the forecast period of 2022 to 2029. Data Bridge Market Research report on hospitality management software market provides analysis and insights regarding the various factors expected to be prevalent throughout the forecast period while providing their impacts on the market's growth. The rise in the adoption of the cloud-based hotel management software is
SCARA Robot Market to Observe Highest Growth of USD 28,345.20 billion with an Excellent CAGR of 27.10% by 2028
SCARA Robot Market to Observe Highest Growth of USD 28,345.20 billion with an Ex …
Global Scara Robot Market study by Data Bridge Market Research provides details about the market dynamics affecting the Scara Robot market, Market scope, Market segmentation and overlays shadow upon the leading market players highlighting the favourable competitive landscape and trends prevailing over the years. A number of estimations and calculations have been included in the first class Scara Robot market report by assuming definite base year and the historic year. The
Ammonium Sulfate Market to Observe Prominent CAGR of 3.85% by 2028, Size, Share, Trends, Demand, Growth, Challenges and Competitive Outlook
Ammonium Sulfate Market to Observe Prominent CAGR of 3.85% by 2028, Size, Share, …
Data Bridge Market research has recently issued comprehensive industry research on Global Ammonium Sulfate Market which includes growth analysis, regional marketing, challenges, opportunities, and drivers analysed in the report. The market insights gained through this Ammonium Sulfate market research analysis report facilitates more defined understanding of the market landscape, issues that may interrupt in the future, and ways to position definite brand excellently. An analysis of competitors is conducted very well

All 5 Releases


More Releases for Drug

Alcohol Testing And Drug Testing Equipment Market 2025 Segmentation, Application …
Market Study Report, LLC, has compiled an exhaustive research study of the ‘Alcohol Testing And Drug Testing Equipment market’, detailing every single market driver and intricately analyzing the business vertical. This ‘Alcohol Testing And Drug Testing Equipment market’ study will aid in seeking out new business opportunities and fine-tuning existing marketing strategies through insights regarding SWOT analysis, market valuation, competitive spectrum, regional share, and revenue predictions. Alcohol abuse and drug
How much Diabetes Drug Market Impact Worldwide Medical Drug Industry?
Diabetes Drug Market From an insight perspective, the market report focuses on various levels of analyses — industry analysis, market rank analysis, and company profiles, which together comprise and discuss basic views on the competitive landscape, high-growth regions, and countries as well as their respective regulatory policies, Types ,Applications and opportunities in the market.  Diabetes is a metabolic disorder in which the body glucose level is elevated. There are two types of diabetes
Hepatitis Drug Market Hepatitis Drug Clinical Pipeline Report 2023
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents 1. Introduction to Hepatitis Disease 1.1 Prologue 1.1.1 History of Hepatitis 1.1.2 Causes of Hepatitis Disease 1.2 Types of Viruses which are Responsible for Hepatitis Disease 2. Global Prevalence of Hepatitis Infection 3. Available Drug Classes for Hepatitis Disease Treatment 3.1 Interferon Alfa Therapy 3.2 Protease Inhibitors Therapy 3.3 Polymerase
Microcapsules Drug Delivery Market Microcapsules Drug Delivery Sales Report 2022
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents 1. Indispensable Advent of Microcapsules 1.1 Trajectory of Microencapsulation 1.2 Why and wherefores for Microencapsulation 2. Characterization of Microcapsules 2.1 Composition of Microcapsules 2.2 Parameters Influencing Microcapsules 3. Engineering Technology of Microcapsules 3.1 Physical Manufacturing Technologies 3.2 Physicochemical and Chemical Technologies 4. Applicability of Microcapsules 4.1 Microcapsules in Pharmaceuticals 4.2 Microcapsules in Nutraceuticals
AstraZeneca’s NMOSD Drug receives orphan drug designation
April 18, 2017 Orphan Drug European Medicine Agency has Announced orphan drug designation for inebilizumab (earlier known as MEDI-551) developed by AstraZeneca PLC (AZN) for the treatment of neuromyelitis optica spectrum disorder (NMOSD). The drug has already received orphan drug status from US Food and Drug Administration (FDA). NMOSD, also called Devic’s disease, is a rare, autoimmune disorder of the central nervous system (CNS) that affects the functioning
Drug Discovery Strategies, PBPK Modeling and Drug-Drug Interaction Explored and …
This year’s 12th annual ADMET conference and exhibition promises to deliver appearances from experienced pharmaceutical professionals from ADME and PK/PD organisations such as AbbVie, GSK, Roche and Bayer when it returns to London this June. The carefully selected speaker line up will be addressing early ADME application strategies and discussing the latest technologically advanced screening and testing models along with exploring ADMET technologies which will identify properties of a drug